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Summary
In the absence of maternal thyroid disease or iodine deficiency, fetal goitre is rare and usually attributable to 
dyshormonogenesis, for which genetic ascertainment is not always undertaken in the UK. Mechanical complications 
include tracheal and oesophageal compression with resultant polyhydramnios, malpresentation at delivery and neonatal 
respiratory distress. We report an Indian kindred in which the proband (first-born son) had congenital hypothyroidism 
(CH) without obvious neonatal goitre. His mother’s second pregnancy was complicated by fetal hypothyroid goitre and 
polyhydramnios, prompting amniotic fluid drainage and intraamniotic therapy (with liothyronine, T3 and levothyroxine, 
T4). Sadly, intrauterine death occurred at 31 weeks. Genetic studies in the proband demonstrated compound 
heterozygous novel (c.5178delT, p.A1727Hfs*26) and previously described (c.7123G > A, p.G2375R) thyroglobulin (TG) 
mutations which are the likely cause of fetal goitre in the deceased sibling. TG mutations rarely cause fetal goitre, and 
management remains controversial due to the potential complications of intrauterine therapy however an amelioration 
in goitre size may be achieved with intraamniotic T4, and intraamniotic T3/T4 combination has achieved a favourable 
outcome in one case. A conservative approach, with surveillance, elective delivery and commencement of levothyroxine 
neonatally may also be justified, although intubation may be required post delivery for respiratory obstruction. Our 
observations highlight the lethality which may be associated with fetal goitre. Additionally, although this complication 
may recur in successive pregnancies, our case highlights the possibility of discordance for fetal goitre in siblings 
harbouring the same dyshormonogenesis-associated genetic mutations. Genetic ascertainment may facilitate prenatal 
diagnosis and assist management in familial cases.
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Background
Congenital hypothyroidism (CH) is the commonest 
neonatal endocrine disorder, (incidence 1:1500 in Europe) 
and a national UK screening programme enables prompt 
diagnosis and initiation of levothyroxine treatment (1). 
Dyshormonogenesis, in which there is inadequate thyroid 
hormone biosynthesis due to a specific defect in one of the 
protein components of the thyroid hormone biosynthetic 
machinery, usually arises due to mutations in the following 
genes: TG, TPO, DUOX2, DUOXA2, IYD, SLC26A4 and 
SLC5A5. European Society for Paediatric Endocrinology 
(ESPE) guidelines recommend genetic counselling in such 
cases, although we have observed interregional variability 
in the proportion of cases undergoing molecular genetic 
ascertainment in the UK (2).
Significant fetal hypothyroid goitre is a rare conse­
quence of fetal dyshormonogenesis, and complications 
include polyhydramnios due to oesophageal compression 
and malpresentation due to neck hyperextension at 
delivery; additionally, neonatal tracheal compression may 
cause fatal respiratory compromise (3, 4). The infrequent 
occurrence of non­autoimmune fetal hypothyroid goitre 
and the risks associated with intrauterine diagnosis and 
therapy have precluded large­scale studies of optimal 
treatment. Intraamniotic T4 may be beneficial in reducing 
goitre size however in the UK, parenteral T4 is not readily 
available, and there is one reported UK case in which 
intraamniotic T3 administered prior to T4 initiation 
achieved a successful outcome. The optimal dosing 
regimen for either drug remains to be ascertained (2, 4, 5).
We describe the second case of hypothyroid fetal 
goitre to be treated with intraamniotic T3 injection whilst 
T4 was being sourced, and the resulting intrauterine 
death which highlights the fetal compromise which 
may occur in this context. Genetic ascertainment in the 
surviving sibling with dyshormonogenic CH showed that 
compound heterozygous TG mutations were the likely 
aetiology for the fetal presentation, enabling appropriate 
genetic counselling to be initiated.
Case presentation
A male infant (Fig. 1: P1) weighing 3.58 kg was born at term 
to non­consanguineous, euthyroid Indian parents after 
an uncomplicated pregnancy. Following an instrumental 
delivery, he required resuscitation (Apgar scores were 5 
(1 min) and 7 (5 min)) and sustained a depressed frontal 
bone and left sided facial nerve palsy due to birth trauma, 
Figure 1
Pedigree diagram for the affected family. Black bars denote those 
individuals who have been genotyped; black and grey shading denotes 
confirmed (P1) and presumed (P2) compound heterozygous genoypes, 
heterozygotes for one of the two mutations are denoted by a central 
black dot.
Learning points:
•	 CH due to biallelic, loss-of-function TG mutations is well-described and readily treatable in childhood however 
mechanical complications from associated fetal goitre may include polyhydramnios, neonatal respiratory 
compromise and neck hyperextension with dystocia complicating delivery.
•	 CH due to TG mutations may manifest with variable phenotypes, even within the same kindred.
•	 Treatment options for hypothyroid dyshormogenic fetal goitre in a euthyroid mother include intraamniotic thyroid 
hormone replacement in cases with polyhydramnios or significant tracheal obstruction. Alternatively, cases may 
be managed conservatively with radiological surveillance, elective delivery and neonatal levothyroxine treatment, 
although intubation and ventilation may be required to support neonatal respiratory compromise.
•	 Genetic ascertainment in such kindreds may enable prenatal diagnosis and anticipatory planning for antenatal 
management of further affected offspring.
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which were conservatively managed. Neonatal screening 
revealed CH (fT4: 7 pmol/L normal range (NR): 9.0–25.0), 
Thyroid­stimulating hormone (TSH) >100 mU/L (NR: 
0.3–5.0)), and a subsequent isotope scan demonstrated 
appropriate uptake in a normally­sited thyroid gland 
(Fig.  2). He had prolonged jaundice but was otherwise 
healthy and prompt initiation of levothyroxine treatment 
has enabled normal growth and development.
There was no family history of thyroid disease 
however his mother exhibited congenital shortened right 
limbs; his father was well and had fathered 4 healthy 
children in a previous relationship (Fig. 1). They went on 
to have a second pregnancy complicated by a fetal goitre 
detected on routine ultrasound (Fig. 3).
Investigation
During the second pregnancy, a 20­week obstetric scan 
revealed a fetal thyroid goitre which continued to 
enlarge between 23 + 3 and 29 + 2 weeks, with associated 
polyhydramnios (Fig. 3). Maternal biochemistry confirmed 
euthyroidism (TSH: 3.2 mIU/L; NR: 0.3–5.0) with absent 
autoantibodies (TPO <20 IU/mL; NR: 0–60), and amniotic 
fluid TSH measurements at 29 + 4 weeks were consistent 
with fetal hypothyroidism: TSH: 1.5 mIU/L (NR <0.51).
Treatment
The large hypothyroid fetal goitre and polyhydramnios 
supported a diagnosis of fetal dyshormonogenesis 
with obstructive dysphagia, due to local oesophageal 
compression. A decision was made to commence 
intraamniotic thyroid hormone replacement, initially by 
injection of 120 µg T3 at 29 + 4 weeks with concomitant 
amniocentesis (260 mL). T3 was selected in the first 
instance due to the fact that we encountered difficulties 
sourcing parenteral T4 in the UK and the requirement for 
local approval to be granted prior to its administration 
would have resulted in significant treatment delay had 
we opted for first­line T4 therapy. At 31 weeks gestation, 
considerable polyhydramnios and fetal hypothyroidism 
persisted (amniotic TSH: 5.3 mIU/L (NR <0.51), compared 
with TSH 1.5 mIU/L at 29 + 4  weeks) therefore 150 µg 
intraamniotic T4 was administered following further 
amniocentesis having been sourced and locally approved 
in the interim.
Outcome and follow-up
At 31 + 3  weeks gestation, an obstetric scan was 
performed for reduced fetal movements, which revealed 
an intrauterine death in association with significant 
polyhydramnios including accumulation of amniotic 
fluid in the extraamniotic/subchorionic space. The 
stillborn infant (P2) was male, weighing 1.62 kg, with a 
normal male karyotype on amniotic fluid analysis. There 
was no evidence of intrauterine infection and postmortem 
was declined.
Although DNA was not extracted from the fetus, 
the history of CH in the elder sibling prompted genetic 
screening of TPO (thyroid peroxidase) and TG 
(thyroglobulin). Compound heterozygous TG mutations 
were identified, comprising a novel, paternally­
inherited single nucleotide deletion (c.5178delT, 
p.A1727Hfs*26), and a maternally­inherited missense 
mutation (c.7123G > A, p.G2375R), which has been 
Figure 2
Technetium-99m pertechnetate thyroid scintigraphy performed in P1 
aged 29 days, demonstrating appropriate radionuclide uptake in a 
normally-sited thyroid gland, consistent with dyshormonogenesis. 
(A) Anterior and (B) lateral images.
Figure 3
Sequential fetal ultrasound images with 
gestational age annotated demonstrating 
progressive fetal goitre (white arrow). A coronal 
view at 23 + 3 weeks gestation demonstrates a 
goitre measuring 42.8 mm × 26.6 mm which 
persists aged 24 + 4 weeks (sagittal view) and has 
enlarged to 54 mm × 36 mm × 52 mm aged 
29 + 2 weeks gestation (sagittal view), 48 h prior 
to intrauterine liothyronine therapy.
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previously reported in association with CH without 
fetal goitre (6) Fig. 4).
Discussion
Although biallelic TG mutations commonly underlie CH 
due to dyshormonogenesis, their absolute frequency is 
low, and fetal goitre is a rare complication which may 
be associated with significant morbidity (3, 7, 8). The 
proband in this family harboured compound heteroygous 
TG mutations, and although the stillborn fetus was not 
genotyped, his goitrous hypothyroidism in utero supports 
an identical genetic diagnosis. Although the proband did 
not have goitre, he exhibited biochemically moderate­
severe CH at diagnosis, and such phenotype variability 
occurs in other kindreds harbouring TG mutations. The 
phenotypic modulators remain uncharacterized although 
dietary iodine intake, (not quantified here), may be 
implicated (9).
ESPE guidelines recommend genetic counselling 
in patients with dyshormonogenetic CH, since most 
patients have an underlying genetic basis. Fetal goitre 
has been reported in association with TG and TPO 
mutations however both discordance and recurrence in 
successive pregnancies has been documented (2, 3, 10). 
A genetic diagnosis in the kindred enabled us to counsel 
the parents that future offspring had a 25% probability of 
inheriting biallelic mutations and developing CH with a 
consequent risk of fetal goitre. In subsequent pregnancies, 
prenatal genetic diagnosis could facilitate management 
by mandating stringent surveillance for fetal goitre, and 
optimization of maternal iodine status. Additionally, 
given the practical difficulties in obtaining parenteral T4 
in the UK, this could be pre­emptively acquired in the 
event of a positive genetic diagnosis in the fetus, in case 
intraamniotic T4 therapy became necessary.
Management of hypothyroid fetal goitre remains 
controversial, as there are significant risks associated 
with both diagnostic amniocentesis/cordocentesis and 
intraamniotic thyroid hormone therapy including 
miscarriage. Although cordocentesis is the gold standard 
for assessment of fetal thyroid status, we felt the clinical 
likelihood of fetal hypothyroidism was high (euthyroid 
mother, negative autoantibodies and brother with CH), 
and therefore measured amniotic fluid thyroid hormone 
levels since this could be achieved simultaneously 
with therapeutic amniocentesis and intraamniotic 
injection (2, 7).
Treatment of fetal hypothyroid goitre requires 
optimization of maternal thyroid status including 
minimizing doses of antithyroid drugs, followed by either 
conservative management with neonatal levothyroxine 
administration, or direct fetal treatment in utero with 
thyroid hormone, since the placenta is not readily 
permeable to maternally­administered thyroxine or 
liothyronine (8, 11). Fetal hypothyroid dyshormonogenic 
goitre in the context of maternal euthyroidism has been 
managed successfully with radiological surveillance, 
followed by elective delivery and neonatal levothyroxine 
treatment, especially in cases presenting at late gestational 
ages. However intubation and ventilation may be required 
to support neonatal respiratory compromise at birth, and 
concerns regarding dystocia may necessitate Caesarean 
section. MRI may be more effective than ultrasound in 
assessing the degree of tracheal compression (8, 12, 13).
Cases treated in utero have usually been given 
intraamniotic levothyroxine, for which one retrospective 
cohort study supports a beneficial effect in reducing 
goitre size. Intraamniotic T3 (three injections of 60, 60 
and 120 µg at 30 + 5–32 + 3  weeks) prior to T4 initiation 
has also been used successfully in another UK case. 
Treatment response is assessed by monitoring goitre size 
and resolution of polyhydramnios, sometimes in addition 
to sequential fetal thyroid hormone measurements. 3D 
ultrasonography may prove a superior tool to standard 
techniques in monitoring fetal goitre size in the future 
Figure 4
Sequencing electropherograms from the proband 
(P1), mother and father, illustrating compound 
heterozygous TG mutations, comprising a novel, 
paternally-inherited single nucleotide deletion 
(c.5178delT, p.A1727Hfs*26), and a maternally-
inherited missense mutation (c.7123G > A, 
p.G2375R).
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(3, 2, 4, 14). The optimal dosing regimen for intraamniotic 
therapy and effect on neonatal thyroid hormone status 
remains undefined, and associated complications 
include premature delivery, intrauterine infection and 
death. Published records describe preterm labour and 
chorioamnionitis following intraamniotic T4, and a case 
of fetal death is alluded to in one report (8, summarized 
in (15)). In view of these caveats, intraamniotic therapy 
is generally considered only when there is progressive 
hydramnios or likely tracheal occlusion, although 
conservative management in this context may also be 
associated with preterm delivery and neonatal death 
(3, 7, 13, 15).
In our patient, logistical barriers (sourcing parenteral 
T4 in the UK, obtaining local approval for therapy) 
initially precluded the use of intraamniotic T4. However 
worsening polyhydramnios compelled us to administer 
an intraamniotic injection of the active thyroid hormone 
T3 (which has a shorter half­life and greater potency than 
T4) until parenteral T4 became available. Treatment with 
intraamniotic T4 would have been preferable to T3, which 
will cause more precipitous fluctuations in hormone 
levels and has only one case report to support its use. The 
precise cause for the intrauterine death in our case was 
undertermined, although significant polyhydramnios 
with extension into the extraamniotic/subchorionic 
space was observed and is likely to have played a major 
role. Additionally, although there was no evidence of 
intrauterine infection, the treatment itself may have 
contributed to fetal demise, given the known risk of fetal 
loss associated with amniocentesis and the short time 
interval between intraamniotic injection and intrauterine 
death. At 31  weeks gestation, we selected a dose of 
intraamniotic T4 similar to that used in the previous 
intraamniotic T3/T4 combination therapy report (150 µg) 
however others have reported successful outcomes with 
higher doses of T4 alone (200–400 µg at similar gestational 
age), raising the possibility this dose was insufficient 
(4, 5). Dysphagia due to tracheo­oesophageal compression 
may also have impaired the ability of the fetus to ingest 
intraamniotic medication such that that earlier initiation 
of thyroid hormone therapy may have been more 
effective (5).
Difficulties in obtaining parenteral T4 in the UK 
compound management of fetal goitrous hypothyroidism 
and our case emphasizes the requirement for further studies 
before T3 is considered a suitable therapeutic alternative. 
Additionally, our report highlights the morbidity and 
mortality associated with hypothyroid fetal goitre and 
its intrauterine treatment, which may be obscured in the 
literature due to a tendency for under­reporting adverse 
outcomes in similar complex cases (8). Although not 
universally undertaken, genetic ascertainment in such 
families may help predict risk of recurrence in future 
pregnancies and guide antenatal management.
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